comparemela.com

Latest Breaking News On - Blue earth therapeutics - Page 8 : comparemela.com

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7 3

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3 - read this article along with other careers information, tips and advice on BioSpace

Siemens healthineers biographDavid gaudenScintomics gmbSiemens healthineersMatthias eiberBruce spottiswoodeTechnical university of munichNuclear medicineDepartment of nuclear medicineClinical applications researchBracco groupBlue earth diagnosticsUniversity hospitalTechnical universityProstate specific membrane antigen targetedEarth diagnostics

Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7 3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer - read this article along with other careers information, tips and advice on BioSpace

United statesScintomics gmbDavide gaudenEugene teohTechnical university of munichNuclear medicineDrug administrationBracco groupEarth diagnosticsNew drug applicationProstate specific membrane antigen targetedBlue earthChief executive officerBlue earth diagnostic phaseTechnical universityChief medical officer

FDA Grants Import Discretion of Bracco s Iodinated Contrast Medium Iomeron® (iomeprol injection) to Address Supply Shortages

MILAN, July 27, 2022 /PRNewswire/ Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., one of the world s leading companies in .

United statesDuccio manettiJeff flemingKimberly gerweckPatheon italiaMicaela colamasiGlobal communicationsDrug administrationBracco diagnostics incPrnewswire bracco diagnostics incBracco groupMarketing communicationsNuclear medicineBracco imaging press officeDiagnostics incChief executive officer

Blue Earth Diagnostics: Independent Clinical Studies Published Regarding Performance of Axumin (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)

- Recently published retrospective studies in Urologic Oncology and Tomography assessed the impact of Androgen Deprivation Therapy (ADT) on Axumin PET imaging - Blue Earth Diagnostics, a Bracco company

Loyola university medical centerUnited statesUnited kingdomNord trøagLoyola universityRoberth wagnerDavide gaudenTrond velde bogsrudCara joycePriscilla harlanDamian grybowskiKostenloser wertpapierhandelClare gidleyEssam rashadMike beyerMedhats gabriel

Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

- Oral presentation highlighted at 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting - Blue Earth Diagnostics, a Bracco company and recognized leader in the development

United statesUnited kingdomPhillip kuoScintomics gmbKostenloser wertpapierhandelDavide gaudenClare gidleyMike beyerPriscilla harlanStudy groupDrug administrationSam brown incBracco groupTechnical university of munichNuclear medicineCorporate communications

vimarsana © 2020. All Rights Reserved.